SERPING1 and hereditary angioedema: Lanadelumab showed a statistically significant improvement in the reduction of attack rates versus C1-INH(IV) in patients with HAE receiving LTP (monthly rate ratio: 0.486; 95% CI: 0.253–0.932) [5].